Dyslipidaemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD) and can be treated with appropriate interventions. The American College of Cardiology/American Heart Association (ACC/AHA) recommends that in adults without ASCVD, traditional ASCVD risk factors, including lipid levels, are assessed every 4-6 years.[2]Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000625
http://www.ncbi.nlm.nih.gov/pubmed/30586774?tool=bestpractice.com
The Centers for Disease Control and Prevention (CDC) recommend more regular screening than this in adults with cardiovascular risk factors (e.g., existing cardiovascular disease [CVD], diabetes, positive family history of lipid disorders).[57]Centers for Disease Control and Prevention. Cholesterol: testing for cholesterol. May 2024 [internet publication].
https://www.cdc.gov/cholesterol/testing/index.html
The use of a validated tool or calculator to predict future risk of ASCVD is recommended.[58]Patel SB, Belalcazar LM, Afreen S, et al. American Association of Clinical Endocrinology consensus statement: algorithm for management of adults with dyslipidemia - 2025 update. Endocr Pract. 2025 Oct;31(10):1207-38.
https://www.endocrinepractice.org/article/S1530-891X%2825%2900972-3/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/40938233?tool=bestpractice.com
In the UK and Europe, lipid screening may begin at age 40 years, although UK guidance recommends a systematic but opportunistic risk-assessment approach targeting adults at increased risk who are above this age, rather than universal screening.[10]Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
https://academic.oup.com/eurheartj/article/41/1/111/5556353
http://www.ncbi.nlm.nih.gov/pubmed/31504418?tool=bestpractice.com
[59]National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. Dec 2023 [internet publication].
https://www.nice.org.uk/guidance/ng238
The European Society of Cardiology (ESC) and European Atherosclerosis Society recommend CVD risk factor screening, including lipid profile testing, be considered in men >40 years old and in women >50 years old and/or who are menopausal, which may then be followed by use of a formal risk assessment tool (such as Systemic Coronary Risk Evaluation-2 [SCORE-2]) in those without ASCVD to decide on prevention strategies in adults over the stated risk thresholds.[10]Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
https://academic.oup.com/eurheartj/article/41/1/111/5556353
http://www.ncbi.nlm.nih.gov/pubmed/31504418?tool=bestpractice.com
[60]Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-337.
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
Note that although the ESC recommends the SCORE-2 risk assessment tool, ideally risk calculators should be population-specific, and clinicians should follow the risk-assessment tools endorsed in their own region or national guidelines.[10]Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
https://academic.oup.com/eurheartj/article/41/1/111/5556353
http://www.ncbi.nlm.nih.gov/pubmed/31504418?tool=bestpractice.com
Screening may begin earlier for those with diabetes in childhood or a family history of dyslipidaemia.
In addition to cardiovascular risk assessment, a positive screening result with markedly raised triglycerides should prompt further evaluation and management to reduce the risk of acute pancreatitis, on an urgent basis.[10]Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
https://academic.oup.com/eurheartj/article/41/1/111/5556353
http://www.ncbi.nlm.nih.gov/pubmed/31504418?tool=bestpractice.com
[58]Patel SB, Belalcazar LM, Afreen S, et al. American Association of Clinical Endocrinology consensus statement: algorithm for management of adults with dyslipidemia - 2025 update. Endocr Pract. 2025 Oct;31(10):1207-38.
https://www.endocrinepractice.org/article/S1530-891X%2825%2900972-3/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/40938233?tool=bestpractice.com